To benchmark the efficacy of alnustone against existing drugs, we compared the therapeutic effects of alnustone with Farnesoid X‐receptor (FXR) agonist obeticholic acid (OCA), a currently used classical drug for clinical treatment of MASLD and is being tested in phase III clinical trials in patients with MASH.[29] OCA was administered with the same dose of alnustone in MCD‐induced MASH mice. Here, XPR1 is linked to metabolic dysfunction-associated steatohepatitis.